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RESEARCH ARTICLE
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Abstract
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that can cause fever and
chronic arthritis in humans. CHIKV that is generated in mosquito or mammalian cells differs
in glycosylation patterns of viral proteins, which may affect its replication and virulence.
Herein, we compare replication, pathogenicity, and receptor binding of CHIKV generated in
Vero cells (mammal) or C6/36 cells (mosquito) through a single passage. We demonstrate
that mosquito cell-derived CHIKV (CHIKVmos) has slower replication than mammalian cell-
derived CHIKV (CHIKVvero), when tested in both human and murine cell lines. Consistent
with this, CHIKVmos infection in both cell lines produce less cytopathic effects and reduced
antiviral responses. In addition, infection in mice show that CHIKVmos produces a lower
level of viremia and less severe footpad swelling when compared with CHIKVvero. Interest-
ingly, CHIKVmos has impaired ability to bind to glycosaminoglycan (GAG) receptors on
mammalian cells. However, sequencing analysis shows that this impairment is not due to a
mutation in the CHIKV E2 gene, which encodes for the viral receptor binding protein. More-
over, CHIKVmos progenies can regain GAG receptor binding capability and can replicate
similarly to CHIKVvero after a single passage in mammalian cells. Furthermore, CHIKVvero
and CHIKVmos no longer differ in replication when N-glycosylation of viral proteins was
inhibited by growing these viruses in the presence of tunicamycin. Collectively, these results
suggest that N-glycosylation of viral proteins within mosquito cells can result in loss of GAG
receptor binding capability of CHIKV and reduction of its infectivity in mammalian cells.
Author Summary
Chikungunya virus (CHIKV) is a chronic arthritis-causing pathogen in humans, for which
no licensed vaccine or specific antiviral drug is currently available. Due to the global
spread of its mosquito vectors, CHIKV is now becoming a public health threat worldwide.
CHIKV can replicate in both mammalian and mosquito cells, however it does not cause
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apparent damage to mosquito cells, yet it rapidly kills mammalian cells within a day after
infection. In addition, mosquito and mammalian cells have different mechanism of pro-
tein glycosylation, which can result in different glycan structures of viral glycoproteins. In
this study, we report that mosquito cell-generated CHIKV has lower infectivity in cell cul-
ture and causes less severe disease in mice, when compared to mammalian cell-generated
CHIKV. We demonstrate that only mammalian cell-generated CHIKV, but not mosquito-
cell generated CHIKV, binds to mammalian cell surface glycosaminoglycan receptors.
Interestingly, mosquito-cell generated CHIKV can re-acquire glycosaminoglycan receptor
binding capability after a single passage in mammalian cells and replicate at similar levels
with mammalian cell-generated CHIKV, suggesting that passage of CHIKV in mosquito
cells can reduce its infectivity.
Introduction
Chikungunya virus (CHIKV) is a mosquito-transmitted, single-stranded RNA virus belonging
to the genus Alphavirus of the family Togaviridae. In humans, CHIKV infection can cause
fever, headache, maculopapular rashes, myalgia, acute joint swelling, persistent arthritis, and
even life-threatening neurological or cardiovascular complications [1–5]. CHIKV was first
identified in Africa in 1952 and has been endemic in the tropical Indian Ocean countries for
decades [6]. In recent years, this virus has caused more widespread and noticeable outbreaks.
From 2004 to 2011, approximately six million cases of CHIKV infection were reported from
nearly forty countries in Africa, Asia, and Europe [6–9]. In recent years, CHIKV mosquito
transmission vectors Aedes aegypti and Ae. albopictus have spread from tropical to temperate
climates, making CHIKV an emerging pathogen within these climate zones [10,11]. In line
with this, CHIKV cases have been recently reported from more than twenty-five countries in
the Caribbean islands, thereby posing a potential threat to North America [12]. Unfortunately,
CHIKV pathogenesis is not well understood, and there is no vaccine or specific antiviral treat-
ment currently available for CHIKV infection [13–15].
CHIKV circulates between mammalian and mosquito hosts and this cyclical transmission
may provide a suitable environment for increased viral fitness and the emergence of more
pathogenic strains [16,17]. Interestingly, re-emergence of CHIKV during the 2005–2006 epi-
demic on Reunion Island was associated with a single point mutation in its genome, which
increased CHIKV fitness within its mosquito vector Ae. albopictus [18]. Additionally, CHIKV
and other alphaviruses differ in their ability to infect mammalian and mosquito cells. For
example, alphaviruses can cause cytopathic effects in mammalian cells and can also shut-down
the mammalian macromolecular machinery involved in cellular protein synthesis at both the
transcription and translational levels [19–21]. In contrast, alphavirus infection of mosquito
cells causes little to no cytopathic effects and does not affect the cellular transcription and
translational processes [21–24].
Mammalian and mosquito cells have distinct cellular enzymatic systems for protein glyco-
sylation; therefore, different post-translational processing of viral surface proteins are possible
in these host cells [25], which can influence replication [26–28], pathogenesis [28,29], trans-
mission [30], and evolution [17] of mosquito-transmitted viruses. In line with this, mamma-
lian- and mosquito-generated arboviruses can bind to different receptors expressed on the
surface of host cells. For instance, differential glycosylation of viral receptor-binding proteins
in mammalian- and mosquito-generated Sindbis virus [31], West Nile virus (WNV) [32], and
dengue virus [33], can affect binding of these virus to host cell receptors. Similarly, mammalian
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cell-generated Ross River virus (RRV), Venezuelan equine encephalitis virus (VEEV), and
WNV can induce more potent interferon responses compared to their mosquito cell-generated
counterparts [34,35]. However, it remains unclear whether CHIKV generation in mosquito
and mammalian cells can affect its infectivity and virulence.
Glycosaminoglycans (GAGs) are highly sulfated polysaccharides that are ubiquitously
expressed on the cell surface and the extracellular matrix of mammalian cells [36,37]. Many
viruses including CHIKV can utilize GAGs as receptors to infect host cells [38]. However,
research on the role of GAG receptor binding in CHIKV and other alphaviruses has been
inconclusive. The GAG receptor binding of CHIKV and other alphaviruses can be acquired
through acquisition of basic amino acids in viral receptor-binding proteins viamutations dur-
ing their continuous passage in cell culture [36,38]. Although such dependence on GAG recep-
tor binding increases viral infectivity in vitro, it can potentially decreases viral fitness in vivo
[39]. In contrast, GAG binding properties have also been described in non-cell culture adapted
alphaviruses, including a clinical strain of CHIKV [40] and a wild-type strain of eastern equine
encephalitis virus (EEEV) [41], suggesting that some other mechanisms that are independent
of cell culture adaptation may also control GAG binding and virulence of CHIKV and other
alphaviruses. Biochemically, GAG receptors possess a negative charge that enables virus-GAG
receptor interaction [40–42]. In addition, mosquito and mammalian cells have different N-gly-
cosylation mechanisms that can generate different configurations of viral glycoproteins [43]
and modulate charge dependent interaction of viruses to host cell receptors. Thus, virus gener-
ation in these different host cells can potentially influence receptor binding and infectivity of
CHIKV. However, the role of mosquito- and mammalian cells on GAG binding capability of
CHIKV and other alphaviruses is unclear.
Herein, we report that CHIKV generated in mammalian cells replicates more efficiently
during its subsequent infection of both human and murine cells in vitro and is more virulent in
a mouse model of CHIKV arthritis, when compared to its mosquito cell-generated counterpart.
We further demonstrate that the reduced replication of mosquito cell-generated CHIKV is
associated with its failure to bind to cell surface GAG receptors on mammalian cells due to dif-
ferential glycosylation of viral proteins in mosquito cells.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recommendations described in the
Guide for the Care and Use of Laboratory Animals of the National Research Council of The
National Academies. The Institutional Animal Care and Use Committee at the University of
Southern Mississippi (Animal Welfare Assurance # A3851-01) reviewed and approved all the
animal care and use procedures under the protocol #12041201.
Biosafety
All in vitro experiments and animal studies involving CHIKV were performed by certified per-
sonnel in biosafety level 3 (BSL3) laboratories, following standard biosafety protocols approved
by the University of Southern Mississippi Institutional Biosafety Committee.
Viruses, cell culture, and chemicals
Low-passaged, Vero cell-generated CHIKV Ross strain (provided by Dr. John F. Anderson,
Connecticut Agricultural Experiment Station) and LR OPY1 2006 strain (provided by Dr. Rob-
ert B. Tesh, University of Texas Medical Branch) were used as parental viral stocks in this
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study. Majority of experiments were performed using the Ross strain and to test strain specific-
ity, some experiments were repeated using the LR OPY1 2006 strain. The viral stocks used in
this study were prepared by a single passage of parental viruses in C6/36 (ATCC, CRL-1660) or
Vero cells (ATCC, CCL-81) and designated as CHIKVmos and CHIKVvero, respectively. All
viral stocks were titered in Vero cells by a plaque-forming assay. C6/36 cells were cultured at
28°C with 5% CO2 in Eagle’s minimum essential media (EMEM, ATCC) supplemented with
10% fetal bovine serum (FBS). Vero cells were cultured at 37°C with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM, Life Technologies) supplemented with 10% FBS. L929
(ATCC, CCL-1), NIH3T3 (ATCC, CRL-1658), Raw 264.7 (ATCC, TIB-71), human foreskin
fibroblasts (HFF, ATCC, CRL-2522), human THP-1 cells (ATCC, TIB-202) and human der-
mal fibroblasts were cultured at 37°C with 5% CO2 in DMEM supplemented with 10% FBS.
To generate murine bone marrow-derived dendritic cells (mBMDC), healthy C57BL/6J
mice (7 weeks old) were euthanized and bone marrow cells were recovered from both femurs.
After red blood cells were lysed, the bone marrow cells were cultured in R10 medium supple-
mented with 10% J558L cell supernatant (as a source of granulocyte-macrophage colony-stim-
ulating factor) at a final density of 1 × 106 cells/ml at 37°C with 5% CO2. The medium was
changed every 3 days and mBMDCs were ready for infection at day 10.
Dermatan sulfate (from porcine intestinal mucosa), chondroitin sulfate A (from bovine tra-
chea), heparin (from porcine intestinal mucosa), sepharose CL-4B, heparin-sepharose, yeast
mannan, tunicamycin, and neutral red were all purchased from Sigma.
In vitro infection
Cells were plated 24 h before infection in 6-, 12- or 24-well plates to 60–80% confluence.
CHIKVmos or CHIKVvero (MOI = 1) were added to the cells and incubated at 37°C for 1 h to
allow for viral adsorption and penetration. The inoculation medium was then replaced with
fresh medium to remove unadsorbed viruses. Cells were washed once with fresh medium and
further incubated at 37°C with 5% CO2 and collected at selected time points for analysis of
viral genome replication and host’s gene expression.
Microscopy and cell viability assay
Cells were infected with CHIKV (MOI = 1 or 5) for 48 h and fixed with 4% paraformaldehyde
(PFA, Electron Microscopy Science). Phase contrast images were acquired using Zeiss LSM510
META confocal imaging system (Carl Zeiss Microscopy, NY). Cell viability was quantified by
toluidine blue (TB) staining, according to the previously published method [44]. Viable cells
were assayed by measuring the absorbance of TB at 630 nm using a microplate reader (BIO-
TEC). Percentage of viable cells was calculated after normalization to uninfected controls.
Real time-quantitative PCR (RT-qPCR)
CHIKV infected cells were subjected to total RNA extraction using TRI-reagent (Molecular
Research Center, Inc.). For RNA isolation from mouse blood samples, RNeasy mini kit (Qia-
gen) was used. The first-strand complementary DNA (cDNA) was synthesized using the
iSCRIPT cDNA synthesis kit (Bio-Rad). RT-qPCR assays were performed in a CFX96 Real-
Time system (Bio-Rad) using SYBR Green supermix (Bio-Rad). Viral RNA copy numbers were
expressed as the ratio of CHIKV envelope-1 (CHIKV E1) to cellular β-actin. For cytokine RT-
qPCR assay, data were presented as relative fold change (RFC) in expression by the ΔΔCT
method after normalized to cellular β-actin. Primer sequences for β-actin of mice [45] and
human [46] were previously described. Primers for CHIKV E1 gene (Forward: TCC GGG
AAG CTG AGA TAG AA; Reverse: ACG CCG GGT AGT TGA CTA TG), and Ae. albopictus
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ribosomal protein 7 gene (Forward: CTC TGA CCG CTG TGT ACG AT; Reverse: CAA TGG
TGG TCT GCT GGT TC) were designed using NCBI online primer designing tool. Primer
sequences for host immune genes (Ifn-α, Ifn-β, Tlr3, Rig-I,Mda-5, and Il-1β) were described in
a previous report [44]. All primers were synthesized by Integrated DNA Technologies.
Plaque forming assay and viral genome copy quantification
Plaque assays were performed according to our previous report with some modifications [47].
Briefly, Vero, L929 or NIH3T3 cells were plated at 5 × 105 cells/well in 6-well plates one day
before infection. Virus-containing samples were added to cell monolayers to allow viral
adsorption/penetration at 37°C with 5% CO2 for 1 h. After removing unadsorbed viruses, cells
were overlaid with 1% SeaPlaque agarose (Lonza) containing medium and further incubated at
37°C with 5% CO2 for an additional 48 h. Plaques were counted after staining with 0.3% neu-
tral red.
CHIKV particles in viral stocks were also quantified by RT-qPCR, as described previously
[38]. Briefly, 200 μl of viral stocks were treated with 50 units (U) of RNase A (Affymetrix) for
1 h at 37°C. TRI-reagent was added to inactivate RNase and lyse viral particles, and viral RNA
was isolated after adding 5 μg of tRNA as carrier. First strand cDNA synthesis and CHIKV E1
gene quantification by RT-qPCR were performed as described above.
Animal studies
Five week old, sex-matched C57BL/6J mice (The Jackson Laboratory) were subcutaneously
inoculated on the ventral side of the right hind footpad toward the ankle with 105 plaque form-
ing units (PFUs) of CHIKVvero or CHIKVmos (Ross strain or LR 2006 OPY 1) in 50 μl phos-
phate buffer saline (PBS), or with 50 μl PBS for mock controls, according to previous
publications [48–50]. Blood samples were collected in 0.5M EDTA by retro-orbital bleeding
and viral RNA in these samples were quantified by RT-qPCR. The height (thickness) and
breath (width) of the perimetatarsal area of inoculated feet were measured daily from day 0 to
day 10 post infection (d.p.i.) by using a digital caliper (Electron Microscopy Science), and the
relative increase in swelling was calculated as previously described [50]. Briefly, footpad swell-
ing was expressed as the relative increase in swelling compared to pre-infection (x d.p.i.– 0 d.p.
i.)/0 d.p.i.).
Histology
Mice were euthanized and inoculated footpad tissues were collected at 6 d.p.i. and fixed over-
night in 4% PFA, followed by decalcification in 10% EDTA for over 10 days. Tissues were then
dehydrated, paraffin embedded, and sectioned (10 μm) with a microtome (American Optical
Spencer 820), followed by staining with hematoxylin and eosin (H&E). The images were
acquired using a bright-field microscope (Olympus BH2).
Attachment assays
CHIKVs (MOI = 1 or 5) were added to cell monolayer for attachment at 4°C for 1 h followed
by washing with fresh medium to remove unattached viruses. The attached viruses were quan-
tified either by RT-qPCR or by a plaque assay in the same cells, as described above. In some
experiments, media containing the unattached viruses were also collected and the unattached
viruses were quantified by a plaque assay in Vero cells to confirm equal numbers of virions
were added to each sample.
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In addition, CHIKV attachment was analyzed by flow cytometry. CHIKVvero or CHIKVmos
(MOI = 2.5) were added to NIH3T3 cells in triplicates in PBS supplemented with 2% FBS
(staining buffer) and were incubated at 4°C for 45 min. Unbound viruses were removed by
washing twice with the staining buffer and the cells were fixed with 2% PFA (Electron Micros-
copy Science) for 15 min at room temperature (RT). After washing, the cells were probed with
mouse monoclonal anti-CHIKV antibody (Abcam) and Cy5 conjugated goat anti-mouse IgG
(KPL) secondary antibody, both for 1 h at RT. The cells were then washed twice and re-sus-
pended in the staining buffer and analysed in a BD LSRFortessa (BD Biosciences) using FACS-
Diva version 6.0 software (BD Biosciences).
Virus entry assays
To assess CHIKVvero and CHIKVmos entry into the host cells, we blocked the endosome acidifi-
cation process using a lysomotrophic agent alone or in combination with a low pH medium
(pH 5.5), the latter mediated viral envelope and cytoplasmic membrane fusion, as previously
described [51,52]. Briefly, infection was carried out in the medium containing 20 mMNH4Cl
to block endosomal acidification. For the direct membrane fusion assay, viruses were allowed
to attach onto cells and then immediately treated with low pH medium for 2 minutes. The
internalized viruses were quantified by RT-qPCR and plaque assays.
Blocking assays for virus attachment
To analyze virus binding to GAG receptors, we performed a GAG neutralization assay, in
which viruses were pre-incubated with soluble GAGs to inhibit their attachment to cell surface
GAG receptors. Briefly, viruses (2.5 x 106 PFU/ml) were pre-incubated with heparin, chondroi-
tin sulfate A or dermatan sulfate (concentration indicated in figures) in DMEM containing 2%
FBS at 37°C for 1 h. The virus-GAGs mixtures were then added to cells (MOI = 1) at 4°C for
1 h to allow attachment. The unattached virus-GAGs mixtures were removed and cells were
washed once with fresh culture medium. The viruses attached to cells were quantified by RT-
qPCR and plaque assays. In some experiments, the effect of heparin-pretreatment on viral rep-
lication was measured at 24 hours post-infection (h.p.i.) by RT-qPCR.
To measure virus binding to lectin receptors such as DC-SIGN and L-SIGN, we performed
a blocking assay in the presence of yeast mannan that disrupts interaction of viruses to cell sur-
face lectin receptors. Briefly, cells were pretreated with different concentrations of yeast man-
nan for 30 minutes at room temperature. Viruses were then added to the cells (MOI = 1) and
incubated at 4°C for 1 h. The viruses attached on cells were quantified by RT-qPCR.
For flow cytometric analysis of GAG neutralization, CHIKVvero or CHIKVmos (2.5 × 10
6
PFU/ml) were pre-incubated with different concentrations of GAGs in DMEM containing 2%
FBS at 37°C for 1 h. Virus-GAGs mixtures were added to NIH3T3 cells in PBS supplemented
with 2% FBS (MOI = 2.5) and incubated at 4°C for 45 min. Cells were washed twice at 4°C to
remove unbound virus and immediately fixed with 2% PFA for 15 min. Cells were then probed
with anti-CHIKV antibody and analyzed by flow cytometry, as described above.
Heparin sepharose bead binding assays
Heparin-conjugated sepharose beads or unconjugated control beads were purchased from
Sigma. The beads (60 μl) were washed twice in 200 μl DMEM, and mixed with 105 PFUs of
CHIKV in a total of 60 μl DMEM containing 2% FBS, and incubated at 4°C for 30 min. The
beads were then washed three times in DMEM containing 2% FBS and the washed solution
was collected for subsequent plaque assays to quantify the unbound viruses. Viruses bound to
beads were lysed in 50 μl of Laemmli sample buffer (Bio- Rad), and viral proteins were
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separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose
membrane (Bio-Rad). After blocked with 5% bovine serum albumin (BSA) for 1 h at RT, the
membranes were probed with mouse monoclonal anti-CHIKV primary antibody (Abcam) at
4°C for overnight on a rocker. The membranes were then washed five times (5 min each) with
Tris-buffered saline with Tween 20 (TBS-T) buffer and reacted with horseradish peroxidase
conjugated goat anti-mouse IgG secondary antibody (Jackson Immunoresearch) for 1 h at RT.
The membranes were then washed and developed using SuperSignal West Pico Chemiluminis-
cence Substrate (Thermo Scientific) and images were acquired using a ChemiDoc MP system
(Bio-Rad).
Sequence analysis
Parental CHIKV viruses (original stocks received from suppliers), single-passaged CHIKV in
Vero cells (CHIKVvero) or mosquito cells (CHIKVmos), and single-passaged CHIKVvero and
CHIKVmos in NIH3T3 cells were subjected to RNA isolation using RNeasy Mini Kit (Qiagen).
cDNA was prepared using the iScript cDNA synthesis kit (Bio-Rad). Complete CHIKV E2
gene was amplified using a Q5 high fidelity polymerase (New England Biolab). The PCR prim-
ers were used according to a previous report [38]. The PCR fragments were purified by Pure-
Link quick PCR Purification Kit (Life Technologies) and sequenced by Functional Biolab.
Concentration of CHIKV and protein glycosylation assays
Stocks of CHIKV (Ross strain) were prepared in Vero and C6/36 cells, UV-inactivated, and
viruses were concentrated by pelleting with 20% sucrose at 28,000 rpm for 2 h in an ultracentri-
fuge (Beckman Coulter). Deglycosylation of viral proteins were carried out using peptide-N-
glycosidase F (PNGase F, Sigma) treatment following the manufacturer’s instruction. Viral
proteins were separated in a 10%Mini-PROTEAN Precast Gels (Bio-Rad) and imaged in a
ChemiDoc MP system (Bio-Rad) after coomassie brilliant blue staining.
Tunicamycin treatment assays
Tunicamycin (TM) was purchased from Sigma and dissolved (10 mg/ml) in cell culture grade
dimethyl sulfoxide (DMSO, ATCC). Vero cells and C6/36 cells were plated for 24 h and
infected with a 0.1 MOI of parental CHIKV (Ross strain). Viruses were allowed to adsorb and
penetrate for 1 h at 37°C. After unadsorbed viruses were removed, the cells were further cul-
tured with medium containing 0.1 μg/ml of TM or the same final concentration of DMSO
(0.001%) as vehicle controls. Cell culture media were collected at 24 h for virus quantification
by plaque assays and RT-qPCR assays. Virus stocks generated in Vero and C6/36 cells in the
presence of TM or DMSO were used to infect NIH3T3 cells (MOI = 0.1) and viral genome rep-
lication was analyzed at 24 h by RT-qPCR.
Statistical analysis
Data were analyzed using GraphPad Prism (version 6.0, GraphPad software) and p< 0.05 was
considered statistically significant. Data were compared using the two-tailed student's t-test or
analysis of variance (ANOVA).
Results
CHIKVmos has a lower level of replication in murine and human cells
Previous reports have suggested that passage of virus through mosquito and mammalian cells
can modulate arboviral infectivity [29,31,43]. To investigate the difference between mosquito
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and mammalian cells generated CHIKV, we prepared CHIKV stocks (Ross strain) by infecting
African green monkey (mammal) kidney cell line (Vero cells) or an Ae. albopictus (mosquito)
cell line (C6/36 cells). Thus generated CHIKV stocks in Vero or C6/36 cells were titered by pla-
que assay in Vero cells and designed as CHIKVvero and CHIKVmos, respectively. CHIKV repli-
cates more efficiently in fibroblastic cells compared to hematopoietic cells [53,54], therefore we
infected mouse embryonic fibroblasts (NIH3T3 cells) with CHIKVmos or CHIKVvero at a mul-
tiplicity of infection (MOI) of 1. At 24 h.p.i., the cells were collected for total RNA extraction
and the first-strand complementary DNA (cDNA) synthesis. CHIKV envelope-1 (E1) gene
RNA copy numbers were quantified by reverse transcription quantitative polymerase chain
reaction (RT-qPCR) and cellular β-actin was used as an internal control. The RT-qPCR results
showed that the level of CHIKVmos replication was significantly lower (approximately
25-folds) than CHIKVvero at 24 h.p.i. (Fig 1A, p< 0.01). In addition, we also confirmed that
CHIKVmos had lower replication in mouse subcutaneous fibroblasts (L929 cells, Fig 1B,
p< 0.05), human foreskin fibroblastic cells (HFF cells, Fig 1C, p< 0.05) and human dermal
fibroblasts (HDF cells, Fig 1D, p< 0.01) at 24 h.p.i. by RT-qPCR assay. To further test whether
CHIKVmos had lower replication over CHIKVvero in cells other than fibroblasts, we compared
their replication in a mouse macrophage cell line (Raw 264.7 cells), primary mouse bone mar-
row derived dendritic cells (mBMDC), and a human monocyte cell line (THP-1). Although
CHIKV replication levels were relatively lower in these immune cells when compared to fibro-
blasts, similar reduction of CHIKVmos replication over CHIKVvero was also observed in Raw
264.7 cells (Fig 1E, p< 0.005), mBMDC (Fig 1F, p< 0.05), and THP-1 cells (Fig 1G,
p< 0.0005). In contrast to murine and human cells, both CHIKVvero and CHIKVmos replicated
similarly when their gene copy numbers were compared in mosquito (C6/36) cells (Fig 1H).
To further study the kinetics of CHIKVvero and CHIKVmos replication over a longer infec-
tion period, we infected NIH3T3 cells with CHIKVvero or CHIKVmos (MOI = 1) and cells were
collected at various time points to analyze CHIKV E1 gene replication by RT-qPCR. In
NIH3T3 cells, levels of CHIKVmos replication was about 30-fold lower than CHIKVvero at 12
and 24 h.p.i (Fig 1I, p< 0.0001), but both viruses replicated at comparable levels at the later
time points (36, 48 and 60 h.p.i). Both CHIKVvero and CHIKVmos also replicated at comparable
levels at 48 h when assayed in L929 cells (Fig 1J). These observations suggest that CHIKVvero
replicates more efficiently than CHIKVmos in murine and human cells during the early time
points. However, over the course of infection in mammalian cells, CHIKVmos may gain its
infectivity and replicates similarly to CHIKVvero.
Besides using PFU/ml as a standard titer for infection assays, we also determined viral titers
by measuring viral genome copies in our viral stocks using RT-qPCR. We infected NIH3T3
cells with equal amounts of genome copies of CHIKVvero and CHIKVmos, and compared their
replication levels by RT-qPCR. Similarly, we observed a significantly lower replication of
CHIKVmos compared to CHIKVvero (S1A Fig), which suggests that the lower replication of
CHIKVmos over CHIKVvero was not due to the difference in unencapsidated viral genome
present in our viral stocks. To test whether our results were specific to the CHIKV Ross strain,
we also compared the replication levels of Vero cell-generated and C6/36 cell-generated
CHIKV-LR OPY1 strain. Similarly, we observed a lower replication of C6/36 cell-generated
CHIKV-LR OPY1 when NIH3T3 cells were infected (S1B Fig). Collectively, these results dem-
onstrate that mosquito cell-generated CHIKV has reduced levels of replication in both murine
and human cells during early stage of infection, when compared to Vero cell-generated
CHIKV.
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Fig 1. CHIKVmos has reduced infectivity than CHIKVvero. (A-H) Indicated cells were infected with CHIKVvero or CHIKVmos (Ross strain, MOI = 1) for 24 h to
measure gene expression of CHIKV E1 and cellular β-actin by RT-qPCR. (I) NIH3T3 cells were infected with CHIKVvero and CHIKVmos (Ross strain, MOI = 1)
for 60 h and CHIKV E1 expression was measured at indicated time points by RT-qPCR. (J) L929 cells were infected with CHIKVvero or CHIKVmos (Ross
strain, MOI = 1) for 48 h to measure gene expression of CHIKV E1 by RT-qPCR. Results were shown as the ratio (mean ± SEM) copy number of CHIKV E1 to
cellular β-actin. Ribosomal protein 7 (rp7) was used as a housekeeping gene control for C6/36 cells. All data represent at least two independent experiments
performed in triplicates with similar results. Replication between CHIKVvero and CHIKVmos were compared using student’s t test (**** denotes p < 0.0001,
and ns denotes p 0.05).
doi:10.1371/journal.pntd.0004139.g001
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CHIKVmos induces moderate cytopathic effects in both murine and
human cells
CHIKV infection can cause cytopathic effects and lysis of mammalian cells [21]. Since
CHIKVmos has a much slower replication than CHIKVvero in both mouse and human cells at
the early time points post infection, we expected that CHIKVmos might also cause less cyto-
pathic effects in these cells. To test this, we infected NIH3T3, L929, HFF, and C6/36 cells with
CHIKVmos and CHIKVvero (Ross strain, MOI = 1 or 5) for 48 h, a time point when cytopathic
effects were clearly visible under a microscope. The microscopy results showed that CHIKVvero
caused more morphological distress and cell death than CHIKVmos in both human and mouse
fibroblasts, but no cytopathic effect was observed in C6/36 cells (Fig 2A). This observation was
further confirmed by a cell viability assay using toluidine blue staining, which showed that
CHIKVmos only caused moderate cytopathic effects compared to CHIKVvero in NIH3T3 (Fig
2B, p< 0.005), L929 (Fig 2C, p< 0.005) and HFF cells (Fig 2D, p< 0.005). In contrast to
murine and human cells, both CHIKVmos and CHIKVvero did not cause any apparent cyto-
pathic effects in C6/36 cells (Fig 2E). To rule out the possibility that the differences in cyto-
pathic effects were not due to Vero and mosquito cell-specific proteins that could be released
in culture supernatant and might be present in our virus stocks, we examined the cytopathic
effects of UV-inactivated CHIKVvero and CHIKVmos stocks in L929 cells. We did not observe
any cytopathic effects until 72 h post-treatment (S1C Fig), suggesting that the observed cyto-
pathic effects were specific to CHIKVvero and CHIKVmos infection.
CHIKVmos induces low levels of antiviral responses
Some mosquito cell-derived viruses including RRV, VEEV andWNV have been reported to
exhibit enhanced infection in primary myeloid dendritic cells due to their inhibition of type I
interferon production when compared to corresponding mammalian cell-derived viral prepa-
rations [34,35,55]. While our results of CHIKVvero and CHIKVmos were opposite to those of
RRV, VEEV and WNV in terms of replication [34,35,55], we asked whether the difference in
CHIKVmos and CHIKVvero replication was due to differential induction of cellular antiviral or
inflammatory responses by these viruses. To test this, we measured the expression profiles of
selected pattern recognition receptors (PRRs) and inflammatory cytokines in CHIKVmos or
CHIKVvero (Ross strain) infected Raw 264.7, L929, NIH3T3, and mBMDC (MOI = 1) by RT-
qPCR assay. In consistent with its lower replication, CHIKVmos induced significantly lower lev-
els of antiviral cytokines (Ifn-α and Ifn-β), proinflammatory cytokine (Il-1β), and PRRs (Tlr3,
Rig-I, andMda-5) in all of the tested cell types at 24 h.p.i. (Fig 3, p< 0.05). Difference in
expression of these genes in CHIKVvero and CHIKVmos infected cells correspond with
replication levels of these viruses in respective cells, suggesting that higher replication of
CHIKVvero over CHIKVmos may not be due to an inhibition of antiviral or inflammatory cyto-
kine expression by these cells. Thus, the slower replication of CHIKVmos in the early stage of
infection might be due to a mechanism that is independent of the host cell antiviral responses.
CHIKVmos causes less severe disease in mice
Differences in in vitro replication of mammalian and mosquito-generated viruses may not
always produce the similar clinical symptoms in a mouse model, as previously reported with
WNV infection [56]. Therefore, we asked whether CHIKVmos and CHIKVvero also differed in
their virulence in vivo. To test this, we infected five-week-old, sex-matched C57BL/6J mice sub-
cutaneously via footpad inoculations with 1 × 105 PFUs of CHIKVmos or CHIKVvero (Ross
strain) or PBS as a vehicle control (mock), according to the previous reports [48–50]. Blood
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Fig 2. CHIKVmos inducesminimal cytopathic effects than CHIKVvero. NIH3T3, L929, HFF, and C6/36 cells were infected with CHIKVmos or CHIKVvero
(Ross strain, MOI as indicated) for 48 h and fixed with 4% PFA after removing culture medium. (A) Phase contrast images (100X) were acquired using a
Zeiss LSM510METAmicroscope. The cell viability data of NIH3T3 (B), L929 (C), HFF (D) and C6/36 (E) cells infected with CHIKVmos or CHIKVvero (Ross
Mosquito Cells Reduce Chikungunya Virus Infectivity
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004139 October 20, 2015 11 / 31
samples were collected on day 1, 2, 4 and 6 post-infection (d.p.i.) for viremia measurement by
RT-qPCR, and footpad swelling was measured daily from 0 to 10 d.p.i.. CHIKVmos produced
lower viremia (presented as CHIKV E1 / β-actin) in mice over the course of infection when
compared to CHIKVvero, which reached statistical significance at 2 d.p.i. (Fig 4A, p< 0.05).
These results suggest that CHIKVmos displays reduced infectivity in mice. Consistent with the
viremia results, CHIKVmos induced milder footpad swelling than CHIKVvero throughout the
experiment (Fig 4B and 4D). Similar results were also obtained when footpad swelling was
compared in mice infected with mosquito cell- and Vero cell-generated CHIKV LR OPY1
strain (Fig 4C and 4D). To further test whether CHIKVmos causes less pathology in mice com-
pared to CHIKVvero, we collected inflamed footpad tissue at 6 d.p.i. and performed a histologi-
cal analysis. We found that CHIKVmos induced less leukocyte infiltration and limited
subcutaneous necrosis in the inflamed foot when compared to CHIKVvero (Fig 4E). Since type
I interferons have been shown to play important roles in CHIKV pathogenesis [53,57], we also
measured expression of Ifn-α and Ifn-β in the blood of CHIKVvero and CHIKVmos infected
mice at 1, 2 and 4 d.p.i. by RT-qPCR.. No significant difference in expression of these genes
was observed between mice infected with CHIKVvero and CHIKVmos (S1D and S1E Fig), sug-
gesting that lower level of swelling in mice infected with CHIKVmos may not be due to differ-
ence in IFN expression, but due to lower infectivity of this virus. All these in vivo data suggest
that CHIKVmos displays lower virulence than CHIKVvero in a mouse model of footpad
swelling.
CHIKVmos has lower ability to attach to host cell surface receptors
To further dissect the mechanism by which CHIKVmos has reduced replication and virulence,
we next compared the plaque-forming phenotypes of CHIKVvero and CHIKVmos in various
cells by plaque assays and counted plaques at 48 h post infection. Consistent with RT-qPCR
results (Fig 1), the plaque assays showed that CHIKVmos had an approximately 25-fold reduc-
tion in PFUs over CHIKVvero in both NIH3T3 and L929 cells (Fig 5A and 5B, p< 0.01) when
equal amounts of virus (~70 PFUs) were used for plaque development. In contrast to the
numbers of PFUs, both CHIKVvero and CHIKVmos formed plaques at 48 h and no difference
in plaque size was observed in all the tested cells (Fig 5A). These results suggest that the lower
replication of CHIKVmos in murine and human cells may be due to its reduced ability to attach
or enter into these cells.
To test whether CHIKVmos attaches to cell receptors at a lower affinity compared to
CHIKVvero, we measured the attachment of CHIKVmos and CHIKVvero (Ross strain, MOI = 5)
on L929, NIH3T3 and HFF cells. Viruses were allowed to bind to the target cells for 1 h at 4°C,
a condition at which most of the viruses attach to cell surfaces but do not enter into cells [58].
Unattached viruses were removed by washing with fresh medium and the viruses attached to
cells were quantified by measurement of CHIKV E1 RNA copies by RT-qPCR. The results
showed that CHIKVmos had significantly reduced attachment to L929, NIH3T3 and HFF cells
(Fig 5C) when compared to CHIKVvero. Similar results were also obtained when mosquito-
and Vero cell-generated CHIKV-LR OPY1 viruses were assayed for their attachment to these
cells by RT-qPCR (Fig 5D). In contrast to murine and human cells, no difference in attachment
between CHIKVvero and CHIKVmos was observed in C6/36 cells (S1F Fig).
To further confirm lower attachment of CHIKVmos, we incubated NIH3T3 cells with
CHIKVvero or CHIKVmos (Ross strain, MOI = 2.5) at 4°C for 45 min, immediately fixed the cell
strain, MOI = 1) for 48 h are presented as the percentage of viable cell as determined by toluidine blue staining. The controls represent cells without viral
infection (Mock). Error bars indicate mean ± SEM. Cell viability data represent two independent experiments performed in triplicates with similar results.
doi:10.1371/journal.pntd.0004139.g002
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Fig 3. CHIKVmos induces lower antiviral responses than CHIKVvero. Raw 264.7 cells, L929 cells, NIH3T3
cells, and mouse bone marrow derived dendritic cells (mBMDC) were infected with CHIKVvero or CHIKVmos
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surface bound viruses with 4% PFA, probed these cells with anti-CHIKV monoclonal antibody,
and analyzed them by flow cytometry. The results showed that CHIKVvero attached to 95% of
these target cells while CHIKVmos attached to only 18% (Fig 5E, p< 0.005), which confirmed
our hypothesis that CHIKVmos has a reduced attachment to host cells, when compared to
CHIKVvero. To further test whether the reduced attachment of CHIKVmos correspond to its
lower infectivity, the viruses attached to these cells were also visualized by plaque development.
For this, we incubated 100 PFUs of CHIKVmos and CHIKVvero (Ross strain) with L929 cells at
4°C for 1 h and washed away unattached viruses. The attached viruses were allowed to develop
plaques for 48 h in a 37°C incubator. To ensure that equal amounts of viruses were used during
this experiment, unattached viral particles were also quantified by a plaque assay in Vero cells.
As expected, the sum of attached and unattached virus matched between CHIKVvero and
CHIKVmos. The attachment results are expressed as percentage using the sum of attached
viruses and unattached viruses as denominator (Fig 5F, p< 0.005). These results showed that
only 2% of CHIKVmos, compared to 45% of CHIKVvero, developed plaques in L929 cells, sug-
gesting a 22.5-fold reduction in plaque development, when viruses were allowed to attach at
4°C. These results were in agreement with the RT-qPCR and plaque assay results showing that
CHIKVmos had approximately 40-fold reduced replication (Fig 1C, p< 0.005) and approxi-
mately 23-fold reduction in plaque numbers (Fig 5A, L929 cells, p< 0.01) in L929 cells when
compared to CHIKVvero. Collectively, these attachment assay results measured by RT-qPCR,
flow cytometry and plaque assays, all suggest that lower replication of CHIKVmos is due to its
reduced attachment to the host cells.
Alphaviruses, including CHIKV, primarily use receptor-mediated endocytosis to enter into
host cells, in which viruses enter the endosome through clathrin-independent endocytosis fol-
lowed by a low pH dependent viral uncoating process in the endosome to gain entry into the
cytoplasm [59,60]. Besides the receptor-mediated endocytosis pathway, direct viral membrane
fusion with the cytoplasmic membrane has also been described as a possible mechanism that
mediates the entry of some alphavirus (e.g. Semliki Forest virus) [61]. To test the possibility
that whether CHIKVvero or CHIKVmos may use different pathways to enter into host cells, we
performed plaque assays in the presence or absence of a lysomotrophic agent (NH4Cl) in
growth media that blocks endosomal acidification and inhibits viral entry through endosomes.
To test direct viral membrane fusion with cytoplasmic membrane, we induced a low pH
mediated viral fusion with the plasma membrane and further cultured cells with or without
NH4Cl. The plaque assay results showed that both CHIKVmos and CHIKVvero fail to develop
plaques in L929 cells (Fig 5G) and Vero cells (S1G Fig) when endosomal acidification was
blocked, suggesting that both types of viruses use receptor-mediated endocytosis, but not direct
viral-plasma membrane fusion, to enter into cells. To further confirm that the receptor-medi-
ated entry of CHIKV occurs through the endosome, we infected L929 cells (MOI = 1) with
CHIKVvero and CHIKVmos in the presence or absence of NH4Cl and analyzed the expression
of CHIKV E1 at 24 h by RT-qPCR. These results further demonstrated that both CHIKVvero
and CHIKVmos enter cells via the endosome pathway (Fig 5H, p< 0.0001).
(Ross strain, MOI = 1) for 24 h. Gene expressions of Tlr3, Rig-I,Mda-5, Il-1β, and type I IFNs (Ifn-α and Ifn-β)
were analyzed by RT-qPCR. The gene copy numbers were normalized to cellular β-actin and the data are
presented as relative fold changes in expression of respective gene compared to the mock-infected control
designated as 1 (not indicated in figures). All data sets represents two independent experiments performed in
triplicates with similar results.
doi:10.1371/journal.pntd.0004139.g003
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Fig 4. CHIKVmos produces lower levels of viremia and footpad swelling in mice.Wild-type C57BL/6J mice were subcutaneously infected with 1 × 10
5
PFUs of CHIKVvero, CHIKVmos or mock infected with PBS and monitored daily for 10 days. (A) Viral load in blood at day 1, 2, 4 and 6-post infection (d.p.i) with
CHIKV (Ross strain) is presented as ratio of CHIKV E1 copy number per 1000 copy of cellular β-actin. Swelling of hind footpad (perimetatarsal area) of mice
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CHIKVvero, but not CHIKVmos, binds to mammalian cell surface
glycosaminoglycan receptors
CHIKV E2 is the major viral protein that mediates binding of CHIKV to host cell surface
receptors [62]. Although a number of cell surface receptors have been described for CHIKV
and other alphaviruses [59,60], the cell surface GAG receptors have been suggested to play a
role in alphavirus infectivity [40–42,63,64]. We asked whether lower attachment of CHIKVmos
was due to its failure to bind to the GAG receptors on host cells. To test this, we performed a
GAG neutralization assay, in which we pre-incubated CHIKVmos or CHIKVvero (Ross strain)
with a range of soluble GAGs (dermatan sulfate and heparin from porcine intestinal mucosa
and chondroitin sulfate A from bovine trachea) at 37°C for 1 h. The virus-GAGmixtures were
added to NIH3T3 cells and cells were further incubated at 4°C for 1 h for viral attachment.
After removal of unattached viruses, the cells were washed once with fresh medium and the
attached viruses were quantified by RT-qPCR. The results showed that pre-treatment with all
the tested GAGs reduced CHIKVvero attachment to NIH3T3 cells in a concentration-depen-
dent manner, but did not affect the attachment of CHIKVmos (Fig 6A). These results suggest
that only CHIKVvero, but not CHIKVmos, may utilize GAG receptors to enter into cells. It has
been previously shown that mosquito cell-generated alphaviruses preferentially bind to lectin
receptors to enter into cells [31]. Thus, it is possible that CHIKVmos uses lectin receptor to
enter into cells. To test this, we performed mannan-blocking assay, in which pre-incubation of
cells with yeast mannan blocks the binding of viruses to lectin receptors, such as DC-SIGN,
L-SIGN and mannose receptors [31,59]. However, preincubation of both NIH3T3 and
HFF cells with yeast mannan (up to 200 μg/ml) did not affect attachment of CHIKVmos or
CHIKVvero in these cells (S1H Fig).
To further confirm GAG receptor binding of CHIKVvero, we also assayed GAG neutraliza-
tion by flow cytometry. Similarly, we observed a concentration-dependent reduction of
CHIKVvero attachment to NIH3T3 cells after GAGs pre-treatment, while attachment of
CHIKVmos was not affected (Fig 6B and 6C). In addition, pretreatment with GAGs also
reduced the plaque development of CHIKVvero but not CHIKVmos (S1I Fig). Similar results
were also obtained when CHIKVmos and CHIKVvero (LR OPY1 strain) were tested for heparin
neutralization in NIH3T3 cells by RT-qPCR (Fig 6D, p< 0.005). These results suggest that
CHIKVvero, but not CHIKVmos, binds to the cell surface GAG receptors.
To further confirm differential effects of pre-incubation with soluble GAGs in CHIKVvero
and CHIKVmos attachment to host cells, we performed a direct GAG binding assay using hepa-
rin-conjugated sepharose beads. Equal PFUs of CHIKVvero or CHIKVmos or their parental
viruses (Ross strain, all generated in Vero cells) were incubated with heparin-conjugated
sepharose beads or unconjugated control beads at 4°C for 30 min. The beads were washed
three times in DMEM containing 2% FBS, and the unbound viruses in the wash solution were
quantified by a plaque assay. Approximately 95% of CHIKVvero, CHIKVmos and their parental
viruses were recovered in the wash solution after incubation with the control beads (Fig 6E,
bottom), suggesting that none of the tested viruses bound onto the control beads. While
approximately 95% of CHIKVmos were recovered in the wash solution after incubation with
the heparin sepharose beads, only about 25% of CHIKVvero, and the parental viruses were
recovered (Fig 6E, bottom), suggesting that only Vero cell-generated CHIKV (CHIKVvero and
(n = 5/group) infected with CHIKV Ross (B) and LR-OPY1 (C) are presented as relative increase in swelling that were calculated by measuring height
(thickness) and breadth (width) of inoculated footpad. (D) Representative image showing footpad swelling after infection with CHIKVmos or CHIKVvero at 6 d.
p.i. (E) H&E stained histological images (100X) of foot tissue at 6 d.p.i displays subcutaneous necrosis (arrow) and infiltrated leukocytes (arrowhead).
CHIKVvero and CHIKVmos data were compared using student’s t test (** denotes p < 0.005, * denotes p < 0.05, and ns denotes p 0.05).
doi:10.1371/journal.pntd.0004139.g004
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Fig 5. CHIKVmos has reduced attachment to host cells than CHIKVvero. (A), Equal PFUs of CHIKVvero or CHIKVmos (Ross strain) were added to Vero
cells (left), NIH3T3 cells (middle) and L929 cells (right) for plaque development. (B), Plaque counts of CHIKVvero and CHIKVmos in the indicated cells were
quantified. (C) L929, NIH3T3 and HFF cells were inoculated with CHIKVvero or CHIKVmos (Ross strain, MOI = 1) at 4°C for 1 h and attached viruses were
quantified by RT-qPCR and presented as the ratio of CHIKV E1 copy number per 1000 copy of cellular β-actin. (D) L929, NIH3T3 and HFF cells were
inoculated with CHIKVvero or CHIKVmos (LR OPY1, MOI = 1) at 4°C for 1 h and viruses attached to cells were quantified by RT-qPCR. (E) NIH3T3 cells were
infected with CHIKVvero or CHIKVmos (Ross strain, MOI = 2.5) at 4°C for 45 min and the virus-bound cells were quantified by flow cytometry. (F) CHIKVvero or
CHIKVmos (100 PFUs) were added to monolayer of L929 cells at 4°C for 1 h and both attached and unattached viruses were quantified by plaque assay to
calculate percentage attachment. (G) CHIKVvero or CHIKVmos (Ross strain, 100 PFUs) were added to the L929 cell monolayer at 4°C for 1 h. After removing
unattached virus, cells were replaced with fresh medium (control), or treated with acidic medium (pH 5.5) for 2 minutes before adding fresh medium, or
replaced with NH4Cl (20 mM) containing media. Viruses that entered into cells were analyzed by allowing plaque development for 48 h and normalized to
controls. (H) Viral RNA copies in L929 cells infected with CHIKVvero or CHIKVmos (Ross strain, MOI = 1) with or without NH4Cl (20 mM) were measured by
RT-qPCR at 24 h.p.i. Data represent at least two independent experiments performed in triplicates with the similar results. ND denotes not detected, and ns
denotes not significant (p 0.05).
doi:10.1371/journal.pntd.0004139.g005
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Fig 6. CHIKVvero, but not CHIKVmos, binds to cell surface glycosaminoglycan receptors. (A) Equal PFUs of CHIKVvero or CHIKVmos (Ross strain) were
pre-incubated with the indicated soluble GAGs at 37°C for 1 h. The virus-GAG complexes were added to NIH3T3 cell monolayer (MOI = 1) and incubated at
4°C for 1 h and the GAGs neutralization of viral attachment was measured by RT-qPCR. Data were normalized to controls without GAG treatment. (B) Equal
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their parental viruses) bound to heparin. These results were also confirmed by western blot by
measuring viruses bound to the heparin sepharose and control beads (Fig 6E, top). Collectively,
the results of GAG neutralization by RT-qPCR, flow cytometry, and direct heparin-conjugated
sepharose bead binding assays demonstrate that only CHIKV generated in Vero cells, but not
in mosquito cells, can attach to cell surface GAG receptors.
To test whether the difference in GAG receptor binding contributes to the different levels of
replication of CHIKVmos and CHIKVvero, we infected NIH3T3 and HFF cells with heparin
pre-treated (1000 U/ml) or untreated CHIKVmos and CHIKVvero (Ross strain) at 37°C
and measured viral replication at 24 h by RT-qPCR. Significant reduction in replication of
CHIKVvero (Fig 6G, p< 0.05), but not CHIKVmos (Fig 6F, p> 0.05), was measured in both
NIH3T3 cells and HFF cells (Fig 6G) after heparin pre-treatment. Of note, CHIKVvero pre-
incubated with heparin had comparable replication to CHIKVmos in both mouse (Fig 6F) and
human cells (Fig 6G), suggesting that the GAG receptor binding of CHIKVvero contributes to
its higher replication, when compared to CHIKVmos.
Mosquito cells eliminate GAG receptor binding of CHIKV
CHIKV E2 is the receptor binding protein of CHIKV. It has been suggested that charge-depen-
dent interaction between the conserved basic amino acid residues in the alphavirus E2 domains
and the negatively charged GAG receptors on mammalian host cell surface facilitate viral
attachment [16,60]. In line with this, GAG receptor binding has been previously reported in
cell-culture adapted alphaviruses, including CHIKV, whereby continuous cell-culture passages
of virus result in acquisition of basic amino acid(s) in the viral E2 glycoprotein viamutations
[38,64]. To test the possibility of potential mutations that could be acquired during CHIKVvero
and CHIKVmos generation through a single passage, we sequenced the receptor binding pro-
tein-encoding gene E2 of CHIKVvero, CHIKVmos, and their parental viral stocks (both Ross
and LR-OPY1 strains). The sequence alignment showed that the E2 gene sequences were iden-
tical among CHIKVvero, CHIKVmos, and their parental stock within each strain (S2 Fig), which
suggested no mutations were acquired in the E2 gene of our CHIKVvero and CHIKVmos stocks
after a single cell passage. In addition, the heparin-sepharose bead assays showed that the
parental viruses, also generated in Vero cells, bound to soluble GAGs (Fig 6E), which indicated
that Vero cell-generated CHIKV lost its GAG binding capability after a single passage in
mosquito cells. To further confirm this, we generated CHIKVmos-NIH and CHIKVvero-NIH
by growing CHIKVmos and CHIKVvero (Ross strain) in NIH3T3 cells for 48 h (single passage)
and compared their replication levels in NIH3T3 and HFF cells at 24 h.p.i. by RT-qPCR. The
results showed that both CHIKVmos-NIH and CHIKVvero-NIH produced a comparable amount
of viral RNA and replicated similarly to CHIKVvero in NIH3T3 cells (Fig 7A) and HFF cells
(Fig 7B). We similarly passaged CHIKVmos and CHIKVvero once for 48 h in L929 to generate
CHIKVmos-L929 and CHIKVvero-L929, or in Vero cells to generate CHIKVmos-VERO and
CHIKVvero-VERO. No differences in replication were observed when CHIKVmos and CHIKVvero
PFUs of CHIKVvero or CHIKVmos (Ross strain) were pre-incubated at 37°C for 1 h with indicated GAGs and added to NIH3T3 cells (MOI = 2.5) at 4°C for 45
min. The virus-bound cells were quantified by flow cytometry and the representative histograms are shown in (C). (D) Heparin (500U/ml) neutralization of
CHIKVvero and CHIKVmos (LR-OPY1 strain) attachment was performed in NIH3T3 cells and measured by RT-qPCR. (E) CHIKVvero, CHIKVmos or their
parental stock (105 PFU, Ross strain) were mixed with heparin-conjugated sepharose beads or unconjugated sepharose beads (control) at 4°C for 45 min
and unbound viruses recovered from beads were quantified by plaque assay in Vero cells (shown in bottom). Input viruses without beads (control) were also
quantified by a plaque assay and viruses recovered from the beads were expressed as percentage of the input. Viruses bound to the respective heparin-
conjugated and control beads were lysed and also analyzed by immunoblotting assays (shown in top). The effect of heparin pre-treatment (1000 U/ml) on
CHIKVvero and CHIKVmos (Ross strain) replication was measured in NIH3T3 (F) and HFF (G) cells at 24 h by RT-qPCR. GAG treated samples were
normalized to their respective controls and analyzed using a one-way ANOVA (**** denotes p < 0.0001, *** denotes p < 0.0005, ** denotes p < 0.005, *
denotes p < 0.05, and ns denotes p 0.05). DS, dermatan sulfate; CSA, chondroitin sulfate A.
doi:10.1371/journal.pntd.0004139.g006
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Fig 7. CHIKVmos infectivity can be enhanced after replication in mammalian cells. The viral stocks of CHIKVvero-NIH3T3 and CHIKVmos-NIH3T3 were
prepared after CHIKVvero or CHIKVmos (Ross strain, MOI = 1) replicated in NIH3T3 for 48 h. (A) NIH3T3 and HFF cells (B) were infected with CHIKVvero,
CHIKVmos, CHIKVvero-NIH3T3 and CHIKVmos-NIH3T3 (MOI = 1), and viral RNA copy numbers were measured at 24 h by RT-qPCR. Data represents ratio of
copy number of CHIKV E1 to β-actin. (C) NIH3T3 cells were infected with CHIKVvero-L929 and CHIKVmos-L929 (MOI = 1), and viral RNA copy numbers were
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passaged once in L929 cells (Fig 7C) or in Vero cells (Fig 7D) were used to infect NIH3T3 cells
for 24 h. These data demonstrate that CHIKVvero and CHIKVmos no longer differ in replication
after their single passage in mammalian cells, suggesting that mosquito cell-mediated reduction
of CHIKVmos replication can be regained after a single passage of CHIKVmos in mammalian
cells.
To further test whether CHIKVvero and CHIKVmos after a single passage in mammalian
cells have a similar level of attachment and GAG receptor binding, we performed attachment
assays and GAG receptor neutralization assays of CHIKVmos-NIH and CHIKVvero-NIH, and
measured the CHIKV E1 gene by RT-qPCR, as described above. The RT-qPCR data showed
that both CHIKVmos-NIH and CHIKVvero-NIH had similar levels of attachment (Fig 7E). In addi-
tion, the RT-qPCR results confirmed that pre-treatment with heparin, dermatan sulfate and
chondroitin sulfate A significantly inhibited attachment of both CHIKVmos-NIH and CHIKV-
vero-NIH onto NIH3T3 cells at similar levels, confirming that CHIKVmos had regained GAG
receptor binding after a single passage through the mammalian cells (Fig 7F). To ensure this
was not due to viral mutation, we also sequenced and compared the E2 gene in CHIKVmos-NIH
and CHIKVvero-NIH, which showed that no mutation occurred in CHIKV E2 gene (S2 Fig).
Collectively, these results indicate that a single passage within mosquito cells can reduce
CHIKV infectivity by eliminating its GAG receptor binding capability.
Mosquito cell glycosylation reduces CHIKV infectivity in mammalian
cells
Mosquito and mammalian cells use different cellular enzymes for N-glycosylation of proteins,
and generate different carbohydrate residues in viral glycoproteins that influence receptor
binding and virulence of viruses [31,43,65]. CHIKV E2, the receptor binding protein, is com-
prised of 423 amino acids with two putative N-linked glycosylation sites at positions 263 and
345 [66]. Therefore, we hypothesized that differential glycosylation of CHIKV receptor binding
protein in mammalian and mosquito cells might lead to differential GAG receptor binding and
therefore influence replication of CHIKVvero and CHIKVmos. To confirm that N-glycosylation
occurs in CHIKV proteins, we treated CHIKVvero and CHIKVmos with PNGase F, an enzyme
that removes N-linked glycan from glycoproteins [67], and analyzed the viral proteins by
SDS-PAGE. We observed shifts in protein bands in the gel after PNGase treatment (Fig 8A),
suggesting that both E1 and E2 proteins are glycosylated in CHIKVvero and CHIKVmos. How-
ever, the composition of glycan at these glycosylation sites differs because the post-translational
modifications within insect cells generate high-mannose oligosaccharides at all glycosylation
sites of viral proteins, while such modifications in vertebrate cells generate both complex and
high-mannose carbohydrates chains at similar glycosylation sites [43,65,68].
To test whether removal of N-glycosylation from CHIKVvero and CHIKVmos affect replica-
tion of these viruses, we infected C6/36 and Vero cells for 20 h with the parental stocks of
CHIKV (Ross strain) in the presence of tunicamycin (TM, 0.1μg/ml), an antibiotic that specifi-
cally inhibits N-glycosylation of proteins [26], or with DMSO as a vehicle control. We analyzed
the effect of TM on virus production in mosquito cells by plaque assays and RT-qPCR.
measured by RT-qPCR at 24 h. (D) NIH3T3 cells were infected with CHIKVvero-VERO and CHIKVmos-VERO (MOI = 1), and viral RNA copy numbers were
measured at 24 h by RT-qPCR. (E) Attachment of CHIKVvero-NIH and CHIKVmos-NIH (MOI = 1) were performed in NIH3T3 cells at 4°C for 1 h and attached
viruses were measured by RT-qPCR. (F) GAGs neutralization of CHIKVvero-NIH3T3 and CHIKVmos-NIH3T3 attachment was performed with heparin (1000 U/
mL), chondroitin sulfate A (CSA, 1000 μg/mL) and dermatan sulfate (DS, 1000 μg/mL) in NIH3T3 cells, and the attached viruses were quantified by RT-qPCR
and normalized to the respective untreated controls. All data sets represent two independent experiments performed in triplicates. GAG-treated samples
were compared to the respective controls (without GAGs) and analyzed using a one-way ANOVA (**** denotes p < 0.0001, *** denotes p < 0.0005,
** denotes p < 0.005, and ns denotes p 0.05).
doi:10.1371/journal.pntd.0004139.g007
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Treatment with TM reduced infectious viral particle production in Vero cells (Fig 8B,
p< 0.001), but not in C6/36 cells (Fig 8C), when measured by plaque assay. Similar to the pla-
que assay results, genome quantification in culture media by RT-qPCR also showed that TM
treatment similarly reduced CHIKV production from Vero cells (Fig 8D, p< 0.001), but not in
C6/36 cells (Fig 8E). In addition, CHIKV generated in C6/36 and Vero cells in the presence of
DMSO or TM has comparable genome to PFU ratio, suggesting that our observations are not
Fig 8. Mosquito cell-specific glycosylation reduces CHIKV infectivity. (A) SDS-PAGE image for CHIKVvero and CHIKVmos proteins that were treated
with PNGase F to remove N-glycans from viral glycoproteins. (B-E) Vero cells or C6/36 cells were infected for 20 h with parental stocks of CHIKV (Ross) in
the presence of tunicamycin (TM, 0.1 μg/ml), or with dimethyl sulfoxide (DMSO) as vehicle controls to measure infectious virus particles released in culture
media by plaque-forming assay (B and C) and the viral genome copies in the culture media by RT-qPCR (D and E). NIH3T3 cells were infected with 0.1 MOI
of CHIKVvero-DMSO and CHIKVmos-DMSO (F), or CHIKVvero-TM and CHIKVmos-TM (G), and viral replication was measured at 24 h by RT-qPCR. (H) GAGs
neutralization of CHIKVvero-TM and CHIKVmos-TM binding was performed with chondroitin sulfate A (CSA, 500 μg/mL) and dermatan sulfate (DS, 500 μg/mL)
in NIH3T3 cells, and the attached viruses were quantified by RT-qPCR. A two-tailed student’s t-test was used for statistical analysis. Error bars indicate
mean ± SEM. ns denotes not significant (p 0.05).
doi:10.1371/journal.pntd.0004139.g008
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due to presence of defective viral particles between groups. These results suggest that N-glyco-
sylation of CHIKV protein can influence its replication in mammalian cells but not in mos-
quito cells.
We further compared the replication of non-glycosylated CHIKVvero and CHIKVmos that
were generated after TM treatment. For this, we infected NIH3T3 cells and measured viral
RNA at 24 h by RT-qPCR. As expected, CHIKVmos has approximately 30-fold lower replica-
tion than CHIKVvero when these viruses are generated in respective cells treated with DMSO
(designated as CHIKVvero-DMSO and CHIKVmos-DMSO, respectively) as vehicle controls (Fig 8F,
p< 0.001). Interestingly, CHIKVvero and CHIKVmos generated in the presence of TM (desig-
nated as CHIKVvero-TM and CHIKVmos-TM, respectively) no longer differed in their replication
in NIH3T3 cells at 24 h (Fig 8G). To further test whether CHIKVvero-TM and CHIKVmos-TM
differ in GAG receptor binding, we performed GAG receptor neutralization assays of these
viruses by RT-qPCR as described above. The RT-qPCR data showed that GAGs pre-treatment
did not inhibit binding of both CHIKVmos-TM and CHIKVvero-TM to NIH3T3 cells (Fig 7H).
These results collectively indicate that mosquito cell-specific N-glycosylation of viral protein
does not favor binding of CHIKV to cell surface GAG receptor and reduces its infectivity in
murine and human cells.
Discussion
Since viruses utilize host cell enzymatic systems to replicate their genome and synthesize func-
tional proteins, viral infection may interrupt normal cellular functions and cause death of the
host cells. However, mosquito-transmitted viruses replicate efficiently in mosquito cells, but do
not cause apparent cellular damage to these cells [22,24]. Therefore, viruses may have adapted
a mechanism to minimize their harmful effects within mosquito cells while replicating in mos-
quito vectors. This may be a viral fitness strategy, whereby a virus can efficiently replicate and
generate a high titer in mosquito vectors, which is necessary for its efficient transmission to
mammalian hosts. Since viral replication uses mammalian and mosquito cellular enzymatic
systems to modify viral structural components [43,69], it could be possible that this fitness
advantage developed in mosquito cells may reduce viral infectivity in mammalian cells [70]. To
test whether mosquito or mammalian cell passages can influence CHIKV infectivity, we com-
pared the replication levels of CHIKVmos and CHIKVvero generated respectively in C6/36
(mosquito, CHIKVmos) or Vero (mammal, CHIKVvero) cells through a single passage. We
observed that CHIKVmos had a significantly lower replication than CHIKVvero in both human
and murine cells, and it also induced moderate cytopathic effects and lower antiviral immune
responses. In contrast, both CHIKVmos and CHIKVvero replicated similarly in C6/36 cells and
did not caused apparent cytopathic effects to these cells (for up to 72 h.p.i.). In a mouse model
of CHIKV-induced footpad swelling, CHIKVmos caused lower viremia, footpad swelling, and
milder histological profiles within the inoculated foot when compared to CHIKVvero. These
results suggest that generation through mosquito cells reduces CHIKV replication in both
human and murine cells and cause a less severe disease in mice.
Previous studies have demonstrated that arboviruses (e.g. Sindbis virus, WNV and dengue
virus) generated in mammalian or mosquito cells can bind to different cell surface receptors
[31–33]. In this study, CHIKVmos replicated at lower levels at the early stages of infection (6 to
24 h) and also developed fewer plaques in both human and murine fibroblasts, compared to
CHIKVvero. However, both CHIKVvero and CHIKVmos produced plaques at the same time
point (approximately 48 h.p.i.) and no difference in plaque size was observed, suggesting only a
portion of inoculated CHIKVmos may initiate productive infection in these cells. Moreover, the
cytokine expression profiles suggest that the higher replication of CHIKVvero over CHIKVmos
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may not be due to suppression of antiviral cytokines, but rather an intrinsic property of the
viral particles generated in two different cell lines. Therefore, we hypothesized that CHIKVmos
might have a lower binding capability to murine and human cell surface receptors compared to
CHIKVvero, which may account for lower replication of CHIKVmos at an early phase of infec-
tion. This hypothesis was proven by the attachment assay and viral entry assay results, which
showed that CHIKVmos had reduced receptor binding to murine and human cells. Although
the cellular receptors for CHIKV and other alphaviruses remain elusive, mammalian cell sur-
face glycosaminoglycan (GAG) receptors are the most extensively studied receptors for alpha-
viruses [64,71,72]. Interestingly, it has been previously demonstrated that a single passage of
RRV (T48 strain) in C6/36 cells resulted in loss of GAG receptor-binding capability, while
RRV derived from mammalian cells bound to GAG receptors [73]. Consistent with this report,
our GAG receptor neutralization and heparin-sepharose bead binding assays showed that
CHIKVmos does not bind to GAG receptors. These results provided evidence for reduced
receptor binding and infectivity of CHIKVmos compared to CHIKVvero. In addition, we also
demonstrated that GAG receptor binding of CHIKVmos could be regained after a single passage
in mammalian cells, indicating that mosquito cells can reduce infectivity of CHIKV by elimi-
nating its ability to bind to GAG receptors on murine and human cells. It is likely that CHIKV-
mos may use some other receptors to enter into cells, and acquire GAG receptor-binding
capability after replication in mammalian cells, which could eventually enhance its infectivity.
Viruses that are generated in different host cells can acquire host cell-specific modifications
on their structural components. For instance, during the viral budding process, enveloped
viruses acquire a portion of the host cell membrane as the viral envelope membrane, resulting
in variable carbohydrate and lipid compositions of these viruses, depending on the cell types in
which they are generated [43,69,74]. In addition, mosquito and mammalian post-translational
modifications, particularly the N-glycosylation, uses different cellular enzymes to modify the
viral glycoproteins [31,65]. Our PNGase F treatment assay results confirm that CHIKV E2, the
receptor binding protein of CHIKV, has N-linked glycosylation sites. However, the composi-
tion of the carbohydrate residues at the glycosylation sites of E2 may vary depending on the
host cell types used for CHIKV generation. Insect cells, including mosquitoes, are deficient in
enzymes for carbohydrate synthesis, including N-acetylglucosaminyl-, galactosyl-, and sialyl-
transferases, resulting in high-mannose oligosaccharides at all glycosylation sites. In contrast,
vertebrate cells can generate both complex and high-mannose carbohydrates chains at these
glycosylation sites [43,65,68]. Glycosylations of Sindbis virus (SINV) E2 at positions 196 and
318 have been documented to play critical roles in receptor binding and infectivity in both cell
culture and in a mouse model [28]. Thus, we hypothesized that differential glycosylation pat-
terns in mammalian and mosquito cells may play a role in differential infectivity of CHIKV
generated in these cell lines. TM is a potent inhibitor of N-glycosylation and it has been previ-
ously shown that viral stocks prepared in the presence of TM lose glycan at their glycolysation
sites [26]. We demonstrated that CHIKVvero and CHIKVmos no longer differed in their replica-
tion when these viruses were prepared in the presence of TM, suggesting that mosquito and
mammalian cell-specific glycosylation can affect the replication of CHIKVvero and CHIKVmos
in murine and human cells. Although we could not completely exclude the possibility that
mosquito cell-specific processing of other structural and nonstructural viral proteins might
also influence the infectivity of CHIKVmos, our data provided several lines of evidence to sup-
port that mosquito cell-specific glycosylation of E2 does not favor GAG receptor binding and
reduces CHIKV infectivity.
Previous studies suggested that mammalian cell-generated RRV, VEEV, and WNV induce
potent IFN responses, but these viruses generated in mosquito cells inhibit IFN production
and replicate more efficiently in mammalian cells in vitro [34,35]. It has been suggested that
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mosquito cell-generated WNV has higher infectivity in vitro [32], however, it produced signifi-
cantly lower viral load in mice compared to mammalian cell-generated WNV during an early
phase of infection, indicating greater infectivity of mammalian cell-generated WNV in vivo
[56]. We found that mammalian (Vero) cell-generated CHIKV possessed greater infectivity in
both in vitro and in vivo conditions. It is possible that the lack of GAG receptor binding of mos-
quito-generated CHIKV may favor its replication in mosquito cells, however this can poten-
tially reduce its infectivity in mammalian cells. This hypothesis is also supported by a recent
report, which showed that RRV had increased fitness in mosquito cells but produced less severe
disease in a mouse model [70].
The role of GAG receptors in viral pathogenesis has been extensively studied in human
immunodeficiency virus [75], herpes simplex virus [76], Echovirus [77], and human papillo-
mavirus [78]. However, the role of GAG receptor binding in alphavirus pathogenicity remains
controversial. Several reports document that cell-culture adapted alphaviruses (about 10–20
generations) can acquire GAG receptor binding capability in vitro via mutations in the E2 gene
that leads to acquisition of basic amino acids [38,64,71,72]. Such GAG receptor dependence,
often described as a cell-culture adapted property, has been suggested to reduce viral pathoge-
nicity in vivo, presumably because of rapid clearance of these viruses from circulation, as
shown in VEEV [39] and SFV [79]. In contrast, GAG receptor binding of cell-culture adapted
SINV has been shown to enhance its infectivity and neurovirulence in mice [42]. It has been
believed that wild-type (non cell-culture adapted) alphaviruses generally do not use heparan
sulfate (HS) receptors, a prototype of GAG receptors, for host cell attachment but depend on
other cell surface receptors including DC-SIGN, L-SIGN, and C-type lectin molecules [31,59].
However, it has been demonstrated that wild-type isolates of eastern equine encephalomyelitis
virus (EEEV) and VEEV that bound to GAG receptors were neurovirulent in mice [41,80].
Unlike other cell culture adapted alphaviruses, the GAG receptor binding capability of wild-
type EEEV does not occur through acquisition of additional basic amino acids in E2 [41]. Simi-
larly, GAG receptor binding property has been also described in a non cell-culture adapted
clinical CHIKV strain, which also occurred independent of additional basic amino acids acqui-
sition in E2 [40]. However, a non cell-culture adapted CHIKV LR strain does not bind to GAG
receptors [57], suggesting that GAG receptor binding may not be a property of all wild-type
CHIKV strains. Herein, we report that mosquito cell-generated CHIKV does not bind on GAG
receptors when compared to Vero cell generated counterpart, but it can acquire GAG receptors
binding capability after a single passage in mammalian cells, such as NIH3T3 and L929 cells.
CHIKV E2 sequencing results further confirmed that the GAG binding ability of mammalian
cell-generated CHIKV was not due to mutation. It is noteworthy that we did not detect any
previously published E2 amino acids in our CHIKV strains that were described to facilitate
GAGs binding of the tissue-culture adapted CHIKV strain [38], suggesting that GAG receptor
binding in our mammalian cell generated CHIKV does not reflect cell-culture adaptation and
occurs without acquisition of basic amino acids. Thus, our results support the notion that the
GAG receptor binding capability in CHIKV and other alphavirus can also be acquired through
mechanisms independent of basic amino acid acquisition in E2 and such GAG binding capabil-
ity can also enhance CHIKV infectivity both in vitro and in vivo.
Attenuation of viruses through a continuous cell-culture passage has been used as a strategy
to develop live-attenuated arboviral vaccines [81–84]. Live-attenuated yellow fever virus vac-
cine (17D strain) is one of the most successful vaccines generated through this approach.
Unfortunately, uses of this approach in an attempt to generate similar vaccines to other viruses
were not successful. Although the detailed molecular mechanisms for attenuation of 17D vac-
cine strain remain elusive, it has been proposed that viral dependence on GAG receptor bind-
ing, particularly HS receptors, which can be acquired during continuous cell-culture passage,
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might play a role [82,84,85]. Recently, GAG-receptor binding CHIKV strains generated
through continuous cell-culture passage has been evaluated as potential vaccine candidates
[38,86,87]. Although GAG receptor dependence has been believed to attenuate alphaviruses in
vivo, some of these CHIKV vaccine strains have been shown to be pathogenic [38]. For exam-
ple, CHIKV vaccine strain (181/25) has been reported to cause transient arthralgia in clinical
trials [88]. Although the selection of GAG receptor dependence has been proposed as a vaccine
developmental strategy, accumulating evidence [38,40,41,89] suggests that other mechanisms
are also possible in attenuation of cell-culture adapted arboviruses. Therefore, strategies to gen-
erate and/or evaluate CHIKV and other arboviral vaccine candidates should not be solely
based on selection of GAG receptor dependence. In addition, viruses may have different affin-
ity of GAG receptor binding or they may bind to different types of GAG receptors that may
affect GAG receptor-dependent CHIKV infectivity in vitro and in vivo, which requires further
investigation.
The mechanisms by which mosquito-transmitted viruses cause minimal or no damage to
mosquito vectors, yet can cause cell death and diseases in mammalian hosts, are not well
understood. The cellular machinery of mosquitos, which prevents CHIKV to bind to GAG
receptors, may favor viral replication in mosquito cells without causing significant cytopathic
effects. Our observation of reduced infectivity of mosquito-generated CHIKV puts forward an
intriguing question of how CHIKV manages to infect hosts during natural infection, when
viruses are inoculated into human skin by a mosquito bite. It has been previously reported that
the mosquito saliva facilitates pathogenicity of some arboviruses, including CHIKV, La Crosse,
dengue, and WNV by inducing CD4+ T helper-2 (Th2) cell dominant anti-inflammatory
responses [90–95]. It is likely that CHIKV may take advantage of mosquito salivary proteins to
initiate early infection in humans. A recent report showed that an Ae. aegypti saliva serine pro-
tease enhanced dengue virus infectivity by increasing the attachment of viruses to HS proteo-
glycans in mammalian hosts [96], suggesting that the reduction in viral GAG receptor binding
by mosquito cells can be compensated by mosquito saliva during natural infections. After inoc-
ulation into the human skin through a mosquito bite, the mosquito cell-derived CHIKV may
use alternative receptors to initiate a low level of infection in human cells. During the course of
infection, CHIKV replicates using human cellular machinery and acquires GAG receptor bind-
ing, resulting in its enhanced infectivity.
In conclusion, this study demonstrates that the infectivity of CHIKV is reduced when gener-
ated in mosquito cells. We show that mosquito cell-generated CHIKV does not bind to GAG
receptors and has reduced attachment to mammalian cells. Furthermore, we provide several
lines of evidence to support that N-glycosylation within mosquito cells may lower infectivity of
CHIKV by removing its ability to bind GAG receptors on murine and human cells. This new
understanding of how mosquito and mammalian host cells alter CHIKV receptor binding and
infectivity may help with the development of effective therapeutics or vaccines against CHIKV
and other mosquito-transmitted viruses.
Supporting Information
S1 Fig. Supplemental figures. (A)NIH3T3 cells were infected with CHIKVvero or CHIKVmos
(Ross strain, 100 viral particles/cell) for 24 h and expression of CHIKV E1 (normalized to cellu-
lar β-actin) was measured by RT-qPCR. (B)NIH3T3 cells were infected with CHIKVvero and
CHIKVmos (LR OPY1 strain, MOI = 1) for 24 h and CHIKV E1 expression was measured by
RT-qPCR. (C) L929 cells were infected with UV-inactivated CHIKVmos or CHIKVvero (Ross
strain) for 72 h and phase contrast images (100X) were acquired using a LSM510 META
microscope (Zeiss). Expressions of Ifn-α (D) and Ifn-β (E) in the blood of wild-type C57BL/6J
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mice infected with CHIKVvero and CHIKVmos (Ross strain, 10
5 PFUs) were measured in blood
by RT-qPCR at day 1, 2, 4 and 6-post infection (d.p.i). (F) C6/36 cells were inoculated with
CHIKVvero or CHIKVmos (Ross strain, MOI = 1) at 4°C for 1 h and the viruses attached to cells
were quantified by RT-qPCR. (H) NIH3T3 and HFF cells were pre-incubated with the indi-
cated concentration of yeast mannan for 1 h at room temperature. CHIKVvero or CHIKVmos
(Ross strain, MOI = 1) were then added to the cells and further incubated at 4°C for 1 h to
allow attachment of viruses. The blocking of viral attachment by yeast mannan was measured
by RT-qPCR. Data were normalized to the control cells without yeast mannan treatment. (I)
One hundred PFUs of CHIKVvero or CHIKVmos (Ross strain) were pre-incubated with heparin
at 37°C for 1 h and then added to Vero cells at 4°C for 1 h for virus attachment. The neutraliza-
tion of plaque development in Vero cells by heparin was measured by plaque assay.
(TIF)
S2 Fig. Sequence alignment data. E2 glycoprotein sequences of different CHIKV stocks used
in this study were shown. Ross strain (black color) and LR OPY1 strain (blue color).
(TIF)
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